Trials of implantable monitoring devices in heart failure

Which design is optimal?

William T. Abraham, Wendy G. Stough, Ileana L. Pina, Cecilia Linde, Jeffrey S. Borer, Gaetano M. De Ferrari, Roxana Mehran, Kenneth M. Stein, Alphons Vincent, Jay S. Yadav, Stefan D. Anker, Faiez Zannad

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Implantable monitoring devices have been developed to detect early evidence of heart failure (HF) decompensation, with the hypothesis that early detection might enable clinicians to commence therapy sooner than would otherwise be possible, and potentially to reduce the rate of hospitalization. In addition to the usual challenges inherent to device trials (such as the difficulty of double-blinding and potential for bias), studies of implantable monitoring devices present unique difficulties because they involve assessment of therapeutic end points for diagnostic devices. Problems include the lack of uniform approaches to treatment in study protocols for device alerts or out-of-range values, and the requirement of levels of evidence traditionally associated with therapeutic devices to establish effectiveness and safety. In this Review, the approaches used to deal with these issues are discussed, including the use of objective primary end points with blinded adjudication, identical duration of follow-up and number of encounters for patients in active monitoring and control groups, and treatment recommendations between groups that are consistent with international guidelines. Remote monitoring devices hold promise for reducing the rate of hospitalization among patients with HF. However, optimization of regulatory approaches and clinical trial design is needed to facilitate further evaluation of the effectiveness of combining health information technology and medical devices.

Original languageEnglish (US)
Pages (from-to)576-585
Number of pages10
JournalNature Reviews Cardiology
Volume11
Issue number10
DOIs
StatePublished - Jan 1 2014

Fingerprint

Heart Failure
Equipment and Supplies
Hospitalization
Therapeutics
Medical Informatics
Clinical Trials
Guidelines
Safety
Control Groups

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Abraham, W. T., Stough, W. G., Pina, I. L., Linde, C., Borer, J. S., De Ferrari, G. M., ... Zannad, F. (2014). Trials of implantable monitoring devices in heart failure: Which design is optimal? Nature Reviews Cardiology, 11(10), 576-585. https://doi.org/10.1038/nrcardio.2014.114

Trials of implantable monitoring devices in heart failure : Which design is optimal? / Abraham, William T.; Stough, Wendy G.; Pina, Ileana L.; Linde, Cecilia; Borer, Jeffrey S.; De Ferrari, Gaetano M.; Mehran, Roxana; Stein, Kenneth M.; Vincent, Alphons; Yadav, Jay S.; Anker, Stefan D.; Zannad, Faiez.

In: Nature Reviews Cardiology, Vol. 11, No. 10, 01.01.2014, p. 576-585.

Research output: Contribution to journalArticle

Abraham, WT, Stough, WG, Pina, IL, Linde, C, Borer, JS, De Ferrari, GM, Mehran, R, Stein, KM, Vincent, A, Yadav, JS, Anker, SD & Zannad, F 2014, 'Trials of implantable monitoring devices in heart failure: Which design is optimal?', Nature Reviews Cardiology, vol. 11, no. 10, pp. 576-585. https://doi.org/10.1038/nrcardio.2014.114
Abraham, William T. ; Stough, Wendy G. ; Pina, Ileana L. ; Linde, Cecilia ; Borer, Jeffrey S. ; De Ferrari, Gaetano M. ; Mehran, Roxana ; Stein, Kenneth M. ; Vincent, Alphons ; Yadav, Jay S. ; Anker, Stefan D. ; Zannad, Faiez. / Trials of implantable monitoring devices in heart failure : Which design is optimal?. In: Nature Reviews Cardiology. 2014 ; Vol. 11, No. 10. pp. 576-585.
@article{73009c88f8814260a81189c2a80f3724,
title = "Trials of implantable monitoring devices in heart failure: Which design is optimal?",
abstract = "Implantable monitoring devices have been developed to detect early evidence of heart failure (HF) decompensation, with the hypothesis that early detection might enable clinicians to commence therapy sooner than would otherwise be possible, and potentially to reduce the rate of hospitalization. In addition to the usual challenges inherent to device trials (such as the difficulty of double-blinding and potential for bias), studies of implantable monitoring devices present unique difficulties because they involve assessment of therapeutic end points for diagnostic devices. Problems include the lack of uniform approaches to treatment in study protocols for device alerts or out-of-range values, and the requirement of levels of evidence traditionally associated with therapeutic devices to establish effectiveness and safety. In this Review, the approaches used to deal with these issues are discussed, including the use of objective primary end points with blinded adjudication, identical duration of follow-up and number of encounters for patients in active monitoring and control groups, and treatment recommendations between groups that are consistent with international guidelines. Remote monitoring devices hold promise for reducing the rate of hospitalization among patients with HF. However, optimization of regulatory approaches and clinical trial design is needed to facilitate further evaluation of the effectiveness of combining health information technology and medical devices.",
author = "Abraham, {William T.} and Stough, {Wendy G.} and Pina, {Ileana L.} and Cecilia Linde and Borer, {Jeffrey S.} and {De Ferrari}, {Gaetano M.} and Roxana Mehran and Stein, {Kenneth M.} and Alphons Vincent and Yadav, {Jay S.} and Anker, {Stefan D.} and Faiez Zannad",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/nrcardio.2014.114",
language = "English (US)",
volume = "11",
pages = "576--585",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Trials of implantable monitoring devices in heart failure

T2 - Which design is optimal?

AU - Abraham, William T.

AU - Stough, Wendy G.

AU - Pina, Ileana L.

AU - Linde, Cecilia

AU - Borer, Jeffrey S.

AU - De Ferrari, Gaetano M.

AU - Mehran, Roxana

AU - Stein, Kenneth M.

AU - Vincent, Alphons

AU - Yadav, Jay S.

AU - Anker, Stefan D.

AU - Zannad, Faiez

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Implantable monitoring devices have been developed to detect early evidence of heart failure (HF) decompensation, with the hypothesis that early detection might enable clinicians to commence therapy sooner than would otherwise be possible, and potentially to reduce the rate of hospitalization. In addition to the usual challenges inherent to device trials (such as the difficulty of double-blinding and potential for bias), studies of implantable monitoring devices present unique difficulties because they involve assessment of therapeutic end points for diagnostic devices. Problems include the lack of uniform approaches to treatment in study protocols for device alerts or out-of-range values, and the requirement of levels of evidence traditionally associated with therapeutic devices to establish effectiveness and safety. In this Review, the approaches used to deal with these issues are discussed, including the use of objective primary end points with blinded adjudication, identical duration of follow-up and number of encounters for patients in active monitoring and control groups, and treatment recommendations between groups that are consistent with international guidelines. Remote monitoring devices hold promise for reducing the rate of hospitalization among patients with HF. However, optimization of regulatory approaches and clinical trial design is needed to facilitate further evaluation of the effectiveness of combining health information technology and medical devices.

AB - Implantable monitoring devices have been developed to detect early evidence of heart failure (HF) decompensation, with the hypothesis that early detection might enable clinicians to commence therapy sooner than would otherwise be possible, and potentially to reduce the rate of hospitalization. In addition to the usual challenges inherent to device trials (such as the difficulty of double-blinding and potential for bias), studies of implantable monitoring devices present unique difficulties because they involve assessment of therapeutic end points for diagnostic devices. Problems include the lack of uniform approaches to treatment in study protocols for device alerts or out-of-range values, and the requirement of levels of evidence traditionally associated with therapeutic devices to establish effectiveness and safety. In this Review, the approaches used to deal with these issues are discussed, including the use of objective primary end points with blinded adjudication, identical duration of follow-up and number of encounters for patients in active monitoring and control groups, and treatment recommendations between groups that are consistent with international guidelines. Remote monitoring devices hold promise for reducing the rate of hospitalization among patients with HF. However, optimization of regulatory approaches and clinical trial design is needed to facilitate further evaluation of the effectiveness of combining health information technology and medical devices.

UR - http://www.scopus.com/inward/record.url?scp=84926073294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926073294&partnerID=8YFLogxK

U2 - 10.1038/nrcardio.2014.114

DO - 10.1038/nrcardio.2014.114

M3 - Article

VL - 11

SP - 576

EP - 585

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 10

ER -